Australian diagnostics firm Proteomics International reported A$1.9 million in Q3 2025 revenue, a more than sevenfold increase year‑over‑year driven by a nonrecurring A$1.7 million collaboration payment from the University of Western Australia (UWA). The partnership aims to build a nationally accredited proteomics platform for clinical biomarker analysis. The company highlighted recent Australian launches of PromarkerD for diabetic kidney disease and a proteomics test for esophageal cancer. Proteomics International reported a reduced quarterly net loss compared with the prior year and ended the period with A$10.0 million cash on hand. Management also disclosed founder Richard Lipscombe plans to retire in February 2026 and the firm has retained a search firm to recruit a successor CEO.